CN100591337C - Medicinal composition for preventing alcoholic liver damage - Google Patents
Medicinal composition for preventing alcoholic liver damage Download PDFInfo
- Publication number
- CN100591337C CN100591337C CN200510056415A CN200510056415A CN100591337C CN 100591337 C CN100591337 C CN 100591337C CN 200510056415 A CN200510056415 A CN 200510056415A CN 200510056415 A CN200510056415 A CN 200510056415A CN 100591337 C CN100591337 C CN 100591337C
- Authority
- CN
- China
- Prior art keywords
- monascus
- monas cuspurpureus
- cuspurpureus went
- herba silybi
- silybi mariani
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A composition used to prepare the medicine or health-care food for relaxing fatty liver and alcoholic liver injury is prepared from silybuflavone and red koji.
Description
Technical field
The present invention relates to a kind of medicine or health food of Herba Silybi mariani-fermented red rice composition, can effectively alleviate the symptom of hepatic disease such as fatty liver, alcoholic liver injury and liver pathological change, delay PD.
Background technology
Alcohol abuse and alcohol dependence have become serious day by day in the world public health problem, calendar year 2001, China's drinks output reached 3,069.87 ten thousand tons, China four drink Epidemiological study of situation of district of drinking is greatly shown, general crowd's the rate of drinking is 59.5%, wherein the male 84.6%, and the women 29.4%, and a year drinking amount is amounted to 3.6 liters of ethanol per capita.
Ethanol has tangible toxic action to liver, and heavy drinking essence person has fatty liver to a certain degree more than 80%, and 10%～35% can develop into alcoholic hepatitis, and 10%～20% will develop into liver cirrhosis.The ratio of the heavy alcoholic liver disease of China hepatopathy crowd increases year by year, and 1991 is 4.2%, and nineteen ninety-five is 17.5%, then is increased to 21.3% by 1996, and the alcoholic liver disease recall rate is 4.3%.
Ethanol mainly contains the risk factor of hepatic disease: take in intravital ethanol more than 90% at liver metabolism, metabolite acetaldehyde can damage the structure function of various cells and enzyme, and can stimulating immune system bring out the immunoreation liver injury; Change to reduced coenzyme (NADH) in the metabolic oxidized form of nicotinamide-adenine dinucleotide (NAD) that causes simultaneously of alcohol oxidation, and then influence the bioprocess that NAD relies on,, cause athero as suppressing the fat oxidation lipid; Too much reduced form covalency thing causes that by promoting that fatty acid is synthetic and suppress its oxidation triglyceride deposits in hepatocyte.Ethanol produces a large amount of free radicals in metabolic process, material produces oxidative damage in the pair cell, and causes the antioxidant (as vitamin A, vitamin E, glutathion etc.) in the liver to be exhausted.In the liver of alcoholic liver disease, produce multiple inflammatory cytokine, and cause immunoreation, cause hepatocyte and sinus hepaticus endothelial cell apoptosis, finally cause liver cirrhosis.In addition, long-term heavy drinking can cause Disorder of Digestion and Absorption and secondary malnutrition and proteins,vitamins,and minerals is lacked.
Still do not have at present the medicine or the therapeutic scheme of specific alcoholic hepatitis, only take the corresponding treatment measure, mainly contain: 1. alleviating alcohol addiction, withdrawal alcohol dependence according to animal experiment; 2. nutritional support; 3. non-specific anti-inflammatory treatment.The medicine of wherein giving up alcohol dependence still upon the look, present medicine has confirmed Linchuan unsatisfactory curative effect or has had potential toxicity, concerning most of alcoholics, secular nutritional support treatment scheme is difficult to accept, and is at present many to hepatitis gravis, hepatic coma or follow the severe malnutrition patient to adopt.The at present glucocorticoids that adopt of non-specific antiinflammatory quality, prolonged application has serious adverse effects, is difficult to a large amount of light, moderate alcoholic liver patient are accepted more.
The tradition traditional Chinese medical science is early on the books to similar disease, and " General Treatise on the Cause and Symptoms of Diseases " claims " wine person, essence-QI from water and grain also, its gas is agile and brave and very toxic; go into then flatulence due to immoderate drinking QI rising in reverse order of stomach, and interior smoking in liver and gall is so the gas liver floats the gallbladder horizontal stroke ", traditional medicine is thought the damp and hot poisonous product of wine number, and after the excessive consumption of alcohol, " alcoholism retention of damp-heat in the interior; liver splenic trauma; disharmony between QI and blood is given birth in expectorant is turbid, the QI and blood phlegm-damp knot of fighting mutually; be stopped at the side of body down, form and amass piece.Delay with the passing of time, liver taste three dirty dysfunctions, water is wet stop gathering in abdomen form tympanites " and replenishing QI to invigorate the spleen, normalizing the stomach by guiding QI downward have been proposed, 8 methods such as the stomach function regulating that helps digestion, and have proved recipes such as Antialcoholic liver-protecting soup, soft livering fat soup to spread.
Monas cuspurpureus Went is the tunning of monascus ruber, as Chinese medicine and fermented food, uses for a long time in China.Traditional medicine thinks, Monas cuspurpureus Went have help digestion invigorate blood circulation, the function of the dry stomach of spleen invigorating.Modern medicine study confirms: Monas cuspurpureus Went can reduce experimental animal serum cholesterol and triglyceride levels, prevent that atheromatous plaque from forming, and visible administration treated animal liver fat range degree is lighter.At present existing " Xuezhikang ", " Sodium Ferulate " etc. are widely used in hyperlipemia based on medicine, the health food of Monas cuspurpureus Went, and hyperlipemia, particularly hypertriglyceridemia is the key factor that fatty liver forms, Monas cuspurpureus Went has tangible accent blood fat, and the effect that suppresses the change of hyperlipidemia animal livers fat is arranged, and the fatty liver tool is had some improvement.
Silymarin is a general name of extracting the isomers of the refining a series of flavone lignin chemical compounds that obtain in the middle of the fruit of feverfew Herba Silybi mariani.Haller was about to the treatment that Herba Silybi mariani is applied to hepatic disease in 1755, at present the preparation of being made by silymarin is widely used in the acute, chronic hepatitis that a variety of causes causes and the treatment of liver cirrhosis in worldwide, long applicating history shows the silymarin determined curative effect, untoward reaction is few, no matter its preparation is as curing mainly or adjuvant drug, all occupying an important position.
Summary of the invention
1. the preparation of composite preparation
See specific embodiment.
2. zoopery:
Choose 70 of healthy Wister male rats, body weight 180～220g, be divided into 7 groups at random, 10 every group, be respectively blank group, positive controls, silymarin group, Monas cuspurpureus Went group, Herba Silybi mariani-fermented red rice composition low dose group, Herba Silybi mariani-fermented red rice composition high dose group, diammonium glycyrrhizinate group.
Except that matched group, each organizes 8 fillings in morning every day stomach Chinese liquor (Red Star board Erguotou wine being diluted by 1: 10 with distilled water) 1 time, dosage increases progressively with the prolongation of duration of experiment, first week was 10ml/100g/d, second week was 15ml/Kg/d, the 3rd week was 20ml/Kg/d, keep the dosage of 12g/Kg/d after the 3rd week, simultaneously matched group is given the normal saline of corresponding dosage, the Herba Silybi mariani group, the Monas cuspurpureus Went group, Herba Silybi mariani-Monas cuspurpureus Went low dose group, Herba Silybi mariani-Monas cuspurpureus Went high dose group, the diammonium glycyrrhizinate group gives corresponding medicine respectively after irritating stomach, and contrast and positive controls give the equivalent normal saline.Each treated animal of experimental session is all given the high nutrient fodder of full price.
Experimental session, positive controls, Monas cuspurpureus Went group, diammonium glycyrrhizinate group rat hair luster degree are poor, body weight gain is slow, most rat appetite are poor, stool is warded off and rushes down, the excitatory state persistent period after Chinese liquor is irritated stomach shortens gradually, the time lengthening of sleeping soundly, wherein the positive controls symptom is remarkable, and has 4 rats deaths in the 10th, 11,12 weeks respectively; The rat above-mentioned symptom occurrence rate of Herba Silybi mariani-Monas cuspurpureus Went high and low dose group, Herba Silybi mariani group, degree to occur all lighter; The blank group rat mental status is good, and appetite is good, and stool is normal.
Get after experiment finishes and respectively organize rat execution, take out rat liver immediately, fixing, the section in the back of weighing, dyeing observation
The liver visual examination: positive controls, Monas cuspurpureus Went group rat liver quality are harder, and color and luster is than the dimness of blank group liver.And 3 Chinese liquor is irritated stomach 12 all rat liver tunicles and adjacent organs has slight adhesion.Matched group, Herba Silybi mariani-Monas cuspurpureus Went high and low dose group rat liver tunicle are smooth, are bronzing, and quality is medium.Other groups are between above-mentioned two states.
Liver histological changes: vacuolar degeneration in various degree appears in positive controls, the most of liver tissues of rats of diammonium glycyrrhizinate group, with the hepatocyte under the Glisson's capsule serves as obvious, endochylema is transparent, the sinus hepaticus pressurized, the disorder of liver rope, the vacuolar degeneration degree increases the weight of with the order of blank group one Herba Silybi mariani-Monas cuspurpureus Went high dose group-Herba Silybi mariani-Monas cuspurpureus Went low dose group-Herba Silybi mariani group-Monas cuspurpureus Went group-diammonium glycyrrhizinate group-positive controls.
Chinese liquor is irritated and respectively to be organized the fat drop that rat all occurs differing in size behind the stomach in the band hepatocyte of lobules of liver center, some liver cell nuclears then by fat drop squeeze obvious off normal.Positive controls is the most serious, and Herba Silybi mariani group, diammonium glycyrrhizinate group are taken second place, and Monas cuspurpureus Went group, Herba Silybi mariani-Monas cuspurpureus Went combined group are then lighter.
All visible point-like of positive controls, Monas cuspurpureus Went group rats'liver lobule or the necrosis of kitchen range shape, in the tissue between the central vein of visible adjacent lobules of liver or and adjacent portal area between bridging necrosis appears; And visible large stretch of hepatic necrosis district, a large amount of inflammatory cell infiltrations in the necrotic area are based on neutrophil cell; The obvious hypertrophy of the visible fibrocyte in some necrotic areas.Other group symptoms alleviate successively according to the order of diammonium glycyrrhizinate group-Herba Silybi mariani group-Herba Silybi mariani-Monas cuspurpureus Went low dose group-Herba Silybi mariani-Monas cuspurpureus Went high dose group.
Each group all sees the little arteriovenous in liver portal area, central veins of hepatic lobules, sinus hepaticus blood stasis and thrombosis, central vein endotheliocytic swelling, portal area fibroplasia for the wine rat.Monas cuspurpureus Went group, Herba Silybi mariani-Monas cuspurpureus Went combined group are lighter.
Positive controls liver tissues of rats red color visible collagen fiber hypertrophy, all visible central veins of hepatic lobules wall thickening, there is obvious red collagen fiber hypertrophy the portal area, and extend in the lobules of liver towards periphery, red color visible collagen fiber hypertrophy in the sinus hepaticus, Herba Silybi mariani-Monas cuspurpureus Went high dose group above-mentioned symptom is not obvious, and above-mentioned situation all appears in other groups, and situation is light than positive controls.
Experiment is got blood after finishing, and centrifugal preparation serum adopts colorimetric method for determining ALT, AST, MDA, GSH and IL-8 with test kit, and the result is as follows:
Table 1. is respectively organized ALT in the rat blood serum, AST measurement result (mol/L)
| Group | ALT | AST |
| Positive controls | 73.65±10.21 | 266.77±21.70 |
| The Herba Silybi mariani group | 45.35±7.62 | 137.89±18.94 |
| The Monas cuspurpureus Went group | 68.43±10.23 | 246.85±20.86 |
| Herba Silybi mariani-Monas cuspurpureus Went low dose group | 42.72±8.55 | 122.76±16.43 |
| Herba Silybi mariani-Monas cuspurpureus Went high dose group | 30.23±7.95 | 89.80±15.06 |
| Sweet Lixin group | 49.67±9.60 | 118.53±16.82 |
| The blank group | 26.77±5.86 | 61.56±10.33 |
Table 2. is respectively organized GSH in the rat blood serum, MDA measurement result (mol/L)
| Group | GSH | MDA |
| Positive controls | 7.65±2.77 | 10.20±3.68 |
| The Herba Silybi mariani group | 40.75±10.98 | 4.08±1.23 |
| The Monas cuspurpureus Went group | 8.91±3.70 | 8.20±2.56 |
| Herba Silybi mariani-Monas cuspurpureus Went low dose group | 33.98±8.90 | 3.77±1.87 |
| Herba Silybi mariani-Monas cuspurpureus Went high dose group | 38.86±10.15 | 3.19±1.05 |
| Sweet Lixin group | 35.72±11.26 | 4.27±1.98 |
| The blank group | 37.66±10.25 | 3.41±0.98 |
Table 3. is respectively organized the measurement result (ng/mL) of IL-8 in the rat blood serum
| Group | IL-8 |
| Positive controls | 1.76±0.21 |
| The Herba Silybi mariani group | 0.49±0.10 |
| The Monas cuspurpureus Went group | 1.12±0.26 |
| Herba Silybi mariani-Monas cuspurpureus Went low dose group | 0.63±0.16 |
| Herba Silybi mariani-Monas cuspurpureus Went high dose group | 0.44±0.18 |
| Sweet Lixin group | 0.77±0.26 |
| The blank group | 0.46±0.11 |
3. interpretation of result
Above-mentioned experimental result shows, irritate stomach with alcohol in high concentration for for a long time rat, infringement to liver is obvious, is presented as mainly on the pathology that the liver quality is hard, that the fat drop, the hepatocyte large tracts of land that occur differing in size in vacuolar degeneration, the hepatocyte in various degree appear in hepatic tissue is downright bad and a large amount of inflammatory cell infiltrations, the visible significantly fibroblast proliferation in necrotic area etc. are arranged; Be presented as then on the diagnostics that ALT, AST, MDA level raise, the GSH level reduces, and produces a large amount of cytokines simultaneously, excites inflammatory reaction.It is relevant that this influences lipid metabolism with ethanol and metabolite thereof, the generation free radical is encroached on cell tissue, the inflammatory reaction of generation cytokine-stimulated etc.In each administration group, above-mentioned damage all has alleviating in various degree, but with Herba Silybi mariani-Monas cuspurpureus Went combined group to alleviate degree the most remarkable, pathological section and blood biochemical analysis to liver organization prove, Herba Silybi mariani-fermented red rice composition not only to enzyme falls, lipid-lowering effect is remarkable, every pathological change to hepatic tissue also has curative effect preferably, and other each groups then do not have this synergism, and its reason is:
1. the flavones ingredient in the silymarin has significant antioxidation, removes the ability that strengthens free radical and metabolite thereof, thereby suppresses lipid peroxidation, alleviates radical damage, plays the hepatocellular effect of protection; By the generation of inhibition TNF-α and TGF-β 1, reduce inflammatory reaction simultaneously, improve the metabolic capacity of hepatocyte, alleviate lipid peroxidation injury and minimizing lipidosis that ethanol and lipid produce ethanol and fat.
2. Monas cuspurpureus Went has the remarkable comprehensive therapeutic effect of very powerful hypercholesterolemia reducing, reduction low-density lipoprotein cholesterol, reduction serum triglycerides, reduction atherogenic index, high density lipoprotein increasing cholesterol, can effectively resist the generation because of the liver fatization that the lipid oxidation level reduces, synthetic level rising causes.
3. the generation of fatty liver and alcoholic liver injury is relevant with multiple factor, the simple medicine that relies on reduces enzyme level, can not be from changing the pathological change that has occurred in essence, in conjunction with present studies show that, have antioxidation, remove free radical, regulate total cholesterol level simultaneously, the comprehensive medicine of adjustment lipid metabolism or drug regimen have more positive meaning and more significant clinical efficacy to the treatment of this class hepatic disease.
In sum, Herba Silybi mariani-fermented red rice composition has powerful synergism in the application of hepatic disease, diseases such as fatty liver, alcoholic liver injury are had significant curative effect, develop its relevant medicine, health food and have higher social meaning and economic benefit.
Also find under study for action; effective ingredient in Herba Silybi mariani and the Monas cuspurpureus Went mostly is the hydrophobicity composition; its oral absorption is relatively poor; for further improving curative effect; we adopt micronize technology and the technology of making solid dispersion to handle respectively; can effectively improve the dissolubility of medicine in water, strengthen absorption, thereby reach the purpose that improves curative effect.
In sum, theing contents are as follows of this invention:
A kind of natural drug composition for the treatment of hepatic injury is made raw materials of effective components and is consisted of by weight: 100～800 parts of Herba Silybi mariani flavones, 50～1400 parts in Monas cuspurpureus Went.
Herba Silybi mariani flavone in the pharmaceutical composition of the present invention is silymarin, silibinin, or contains the Herba Silybi mariani flavone extract that surpasses 15% silibinin.
Pharmaceutical composition of the present invention, the fungus that produces Monas cuspurpureus Went is a monascus, Mauve aspergillar, the monascus that turns white, Bark monascus, smoky gray monascus, red monascus, rust monascus, the monascus that reddens, or any kind in the Mucor shape monascus.
The application of pharmaceutical composition of the present invention in preparation treating liver injury medicine or health food.
The preparation that pharmaceutical composition of the present invention is made.
The preparation that pharmaceutical composition of the present invention is made, its preparation are tablet, dispersible tablet, effervescent tablet, capsule, drop pill, granule or oral liquid.
The application of pharmaceutical composition of the present invention in preparation treating liver injury medicine or health food; it is characterized in that adding the nutrient substance that promotes liver metabolism, be specially one or more the mixture in vitamin, aminoacid, soybean phospholipid, inosine, coenzyme, taurine and the animal livers extract.
Specific implementation method
Embodiment one, Herba Silybi mariani-fermented red rice composition preparation tablets
Prescription is formed:
Silymarin 55g
Monas cuspurpureus Went 273.0g
Microcrystalline Cellulose 38g
Micropowder silica gel 12g
Stearic acid 18g
Lactose 11g
Magnesium stearate 1g
Make 1000
Method for making: get Monas cuspurpureus Went, pulverized 100 mesh sieves, mix, add all the other central adjuvants of prescription: microcrystalline Cellulose, micropowder silica gel, stearic acid and lactose with the silymarin of handling through micronize; mixing is made granule, and drying adds magnesium stearate; mixing, tabletting, promptly.
Embodiment two, Herba Silybi mariani-fermented red rice composition capsule preparation
Prescription is formed:
Water flies guest's phosphatide complexes (4/1) 20g
Monas cuspurpureus Went 280.0g
Pregelatinized Starch 25g
Micropowder silica gel 8g
Make 1000
Method for making: get silibinin, add phosphatidase 15 g, behind dissolve with ethanol, filter, volatilize, drying obtains the silibinin phosphatide complexes; Get Monas cuspurpureus Went and pulverized 100 mesh sieves,, add the disintegrating agent pregelatinized Starch with silibinin phosphatide complexes mix homogeneously, mix homogeneously, last and micropowder silica gel mixing, the capsule shells of packing into No. 2, promptly.
Embodiment three, Herba Silybi mariani-fermented red rice composition dispersible tablet preparation
Prescription is formed:
Herba Silybi mariani flavone extract (micronize) 200g (containing 20% silibinin)
Monas cuspurpureus Went ethanol extraction (micronize) 20.0g
Lactose 50g
CMS-Na 25g
Microcrystalline Cellulose 50g
L-HPC 25g
5%PVP K30 is an amount of
Magnesium stearate 3g
Make 1000
Method for making: according to above-mentioned prescription, the principal agent after the micronize of learning from else's experience is handled, the CMS-Na that adds microcrystalline Cellulose, L-HPC, crosslinked CMC-Na, 1/3 recipe quantity puts in the wet-mixing granulator, mixed 2min, add adhesive (5%PVP K30 alcoholic solution), 30 mesh sieves are granulated, 50-80 ℃ of drying; Dried granule is crossed 20 mesh sieve granulate, adds magnesium stearate and micropowder silica gel in the middle of dried particles, and the CMS-Na and the remaining mannitol that remain 2/3, mixing, and tabletting, packing promptly gets the compositions dispersible tablet.
Embodiment four, Herba Silybi mariani-fermented red rice composition drop pill preparation
Prescription is formed:
Silibinin 15g
Monas cuspurpureus Went ethanol extraction 20.0g
Phosphatidase 11 0g
PEG 6000 30g
Make 1000
Method for making: polyethylene glycol 6000 is put in the container, heating and melting in 85～90 ℃ oil bath, add silibinin and Monas cuspurpureus Went ethanol extraction immediately, stir, move into drop pill machine reservoir then, airtight and the insulation at 80～85 ℃, the system of dripping, the drop pill that oozes cools off through 10～15 ℃ liquid paraffin, and drop is paraffin to the greatest extent, make 1000, promptly.
Embodiment five, Herba Silybi mariani-fermented red rice composition dry suspension (granule) preparation
Prescription is formed:
Silybin-N-methylglucamine 50g
Monas cuspurpureus Went ethanol extraction 70.0g
Taurine 100g
PVP 20.0g
Arabic gum 70g
Xanthan gum 60g
Sucrose 800g
Essence 10g
Make 1000 bags
Method for making: get the Monas cuspurpureus Went ethanol extract, be equivalent to the 70g extract, add PVP under the condition of heating, spray drying obtains Monas cuspurpureus Went-PVP solid dispersion; According to above-mentioned preparation prescription, in the Monas cuspurpureus Went dispersion, add silybin-N-methylglucamine, taurine, sucrose, Radix Acaciae senegalis, sodium carboxymethyl cellulose, xanthan gum, orange flavor mix homogeneously, with an amount of 75% alcohol granulation; dry; granulate, packing, promptly.
Embodiment six, Herba Silybi mariani-fermented red rice composition effervescent tablet
Prescription is formed:
Silymarin 180g
Monas cuspurpureus Went 200g
Vitamin C 100g
Citric acid 1291g
Sodium bicarbonate 1600g
Sodium lauryl sulphate 45g
Make 1000
Method for making: silymarin and the Monas cuspurpureus Went mix homogeneously of getting recipe quantity, other gets citric acid (about 4 hours of the first 60-70 ℃ drying of recipe quantity, 120 ℃ of dryings then), sodium bicarbonate, Vc, compacting is large stretch of, crossing 16 mesh sieves granulates, the sodium lauryl sulphate mixing that adds recipe quantity, tabletting promptly adopt the plastic tube multiple dose to pack.
Embodiment seven, Herba Silybi mariani-fermented red rice composition oral liquid
Prescription is formed:
Silibinin-phthalic monoester sodium salt 40g
Monas cuspurpureus Went extract (60% ethanol extraction) 200g
Inosine 100g
Must aminoacid 300g
Ethyl hydroxybenzoate 1g
Saccharin sodium 2g
Menthol spirit 15ml
Distilled water adds to 20000ml
Make 1000 bottles
Method for making: get distilled water 1000ml, boil, add cyclamate, saccharin sodium and ethyl hydroxybenzoate, after the stirring and dissolving, filter, add principal agent in the filtrate, stirring and dissolving is put coldly, adds menthol spirit and an amount of distilled water, and making full dose is 20000ml, stir evenly, sterilization, packing, promptly.
Claims (7)
1, a kind of natural drug composition for the treatment of hepatic injury is characterized in that making raw materials of effective components and consists of by weight: 100～800 parts of Herba Silybi mariani flavones, 0 part in Monas cuspurpureus Went 50～14 ().
2, natural drug composition according to claim 1 is characterized in that described Herba Silybi mariani flavone is silymarin, silibinin, or contains the Herba Silybi mariani flavone extract that surpasses 15% silibinin.
3, natural drug composition according to claim 1, the fungus that it is characterized in that producing Monas cuspurpureus Went is a monascus, Mauve aspergillar, monascus turns white, the Bark monascus, smoky gray monascus, red monascus, the rust monascus, the monascus that reddens, or any kind in the Mucor shape monascus.
4, a kind of according to the application of the described natural drug composition of claim 1 in preparation treating liver injury medicine or health food.
5, the preparation made of a kind of natural drug composition according to claim 1.
6, the preparation made of natural drug composition according to claim 5 is characterized in that described preparation is tablet, dispersible tablet, effervescent tablet, capsule, drop pill, granule or oral liquid.
7, a kind of according to the application of the described natural drug composition of claim 4 in preparation treating liver injury medicine or health food, it is characterized in that adding one or more the mixture in vitamin, aminoacid, soybean phospholipid, inosine, coenzyme, taurine and the animal livers extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200510056415A CN100591337C (en) | 2005-03-23 | 2005-03-23 | Medicinal composition for preventing alcoholic liver damage |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200510056415A CN100591337C (en) | 2005-03-23 | 2005-03-23 | Medicinal composition for preventing alcoholic liver damage |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1686519A CN1686519A (en) | 2005-10-26 |
| CN100591337C true CN100591337C (en) | 2010-02-24 |
Family
ID=35304561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200510056415A Expired - Fee Related CN100591337C (en) | 2005-03-23 | 2005-03-23 | Medicinal composition for preventing alcoholic liver damage |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100591337C (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101062097B (en) * | 2007-06-11 | 2011-05-04 | 毛晓敏 | Compound for improving and treating fatty liver |
| CN101647845B (en) * | 2008-08-13 | 2011-11-30 | 张晶 | Natural product composition used for reducing blood fat and preparation method thereof |
| CN104288181B (en) * | 2014-10-27 | 2018-05-04 | 武汉中博绿亚生物科技有限公司 | It is a kind of to treat pet because expelling parasite causes paste for not relaxing and preparation method thereof |
| CN104435147A (en) * | 2014-12-08 | 2015-03-25 | 南京泛成生物化工有限公司 | Composition for preventing and treating non-alcoholic fatty liver disease and application thereof |
| CN117448178B (en) * | 2023-10-31 | 2024-04-26 | 湖北嫦娥生物股份有限公司 | Monascus purpureus CEWL and application thereof in preparation of liver protection products |
-
2005
- 2005-03-23 CN CN200510056415A patent/CN100591337C/en not_active Expired - Fee Related
Non-Patent Citations (4)
| Title |
|---|
| 水飞蓟素药学研究进展. 杨晋等.天然产物研究与开发，第16卷第2期. 2004 |
| 水飞蓟素药学研究进展. 杨晋等.天然产物研究与开发，第16卷第2期. 2004 * |
| 红曲的生产及其应用 . 田莉，程剑峰.农产品加工，第5期. 2003 |
| 红曲的生产及其应用. 田莉，程剑峰.农产品加工，第5期. 2003 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1686519A (en) | 2005-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101011561B (en) | Modern traditional Chinese medicine oral preparation huanglianwendan decoction and production method thereof | |
| CN101502627B (en) | Chinese medicine health product preparation for preventing and treating alcoholic liver disease and preparation method thereof | |
| CN106244371B (en) | A kind of hypoglycemic rhizoma polygonati grape health care wine and its production technology | |
| WO2011060585A1 (en) | Chewable tablets including essences of five-colour fruits and vegetables and preparative methods thereof | |
| CN100591337C (en) | Medicinal composition for preventing alcoholic liver damage | |
| CN1857475A (en) | Composition for preventing and treating cardias and cerebral vascular diseases and its application | |
| CN101766274A (en) | Antioxidant functional food composition containing bamboo-leaves flavones | |
| CN105250821B (en) | A kind of compound Chinese medicinal preparation and preparation method thereof for treating ulcerative colitis | |
| CN105708970B (en) | A kind of health food with function of blood sugar reduction | |
| CN104388236A (en) | Grape wine as well as preparation method and application thereof | |
| CN105560779B (en) | The compound preparation and application thereof for preventing and treating non-alcohol fatty liver | |
| CN102188486B (en) | Pharmaceutical composition for preventing and treating fatty liver and preparation method thereof | |
| CN108143974A (en) | Relieving alcoholism and protecting liver ball | |
| CN103735621B (en) | A kind of Chinese medicine composition with blood fat reducing and enhancing immunity effect | |
| CN114767826B (en) | Sobering-up liver-protecting composition, beverage with sobering-up liver-protecting efficacy and preparation method thereof | |
| CN114053384B (en) | Composition for treating or preventing inflammatory bowel disease, and preparation method, preparation and application thereof | |
| CN101574509A (en) | Agerasia preparation | |
| CN106266811A (en) | A kind of Chinese medicine composition for improving department of chemistry's hepatic injury and its preparation method and application | |
| CN102727481B (en) | Medicinal composition containing levocarnitine and hydroxyphenyl sulfonate | |
| CN1261096C (en) | Compound preparation of reveratrol and application | |
| CN104799276B (en) | Panax notoginseng and gastrodia elata powder for promoting normal circulation of blood and thrombolysis, and preparation method thereof | |
| CN1660207A (en) | Preparation of health care for reducing blood fat and cholesterol, and producing method | |
| CN114515009B (en) | Composition with weight-losing and lipid-lowering effects and application thereof | |
| CN100379449C (en) | Compositions of SOD and vetetative medicine or its extractives, and its prepn. method | |
| CN109528827B (en) | Pharmaceutical composition and preparation for promoting blood circulation, removing blood stasis and reducing blood fat and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100224 Termination date: 20100323 |